Horseshoe crabs are harvested by the millions annually for their medically valuable blue blood. The harvesting process causes significant mortality and welfare harm to a species of ancient ecological importance.
Horseshoe crabs occupy a complex position in animal welfare considerations. Their neurological complexity and capacity for suffering are less well understood than in vertebrates, yet harvesting involves prolonged handling, bleeding, and transport stress that causes measurable mortality. The downstream ecological harm — reduced crab populations and depleted egg resources for migratory shorebirds — compounds the direct welfare impact. The existence of a validated synthetic alternative makes continued large-scale harvesting a choice rather than a necessity. Transitioning the pharmaceutical industry to synthetic alternatives is both a horseshoe crab welfare improvement and a conservation measure that benefits the entire ecosystem they support.